Systemic Candidiasis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Systemic Candidiasis – Drugs In Development, 2024 report and make more profitable business decisions.
Systemic candidiasis encompasses a range of yeast infections resulting from various species of Candida, presenting a severe threat that can impact diverse areas of the body such as the blood, heart, brain, eyes, bones, and other organs. While there are over 200 Candida species, five specific types contribute to 90% of systemic candidiasis cases. The primary manifestation of this invasive yeast infection occurs when Candida infiltrates the bloodstream, leading to candidemia. Indications of candidemia include persistent fever and chills unresponsive to antibiotics. Symptoms of other forms of Systemic candidiasis vary depending on the affected organ or system. Particularly prevalent among hospitalized individuals in high-income countries, including the US, systemic candidiasis poses diagnostic challenges, especially when Candida is not detected in the bloodstream.
The Systemic Candidiasis drugs in development market research report provide comprehensive information on the therapeutics under development for Systemic Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Candidiasis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Systemic Candidiasis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 25 molecules, with 24 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Systemic Candidiasis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Systemic Candidiasis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Systemic Candidiasis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Autoimmune Technologies LLCBasilea Pharmaceutica Ltd
Cidara Therapeutics Inc
Cisen Pharmaceutical Co Ltd
Concerto Biosciences Inc
Female Healthcare Purna
Gedeon Richter Plc
Grupo Ferrer Internacional SA
Jiangsu ProteLight Pharmaceutical & Biotechnology Co Ltd
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Oryn Therapeutics
Osel Inc
Pfizer Inc
Profem GmbH
Pulmonomy Inc
Riptide Bioscience Inc
Sano Chemicals Inc
SaNOtize Research and Development Corp
Satellos Bioscience Inc
Scynexis Inc
State University of New York at Buffalo
Toltec Pharmaceuticals LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Systemic Candidiasis reports